Lori Martin Gregory
Lori Martin Gregory is a reluctant activist who uses her background as a strategic consultant and fourth generation journalist to promote health freedom.
She was graduated with a BA in Journalism from Metropolitan State College in Denver and an MBA from Boston University. She also has a diploma in Complementary Medicines from The Open University in Sri Lanka and has been teaching Ayurveda, yoga, and meditation for 25 years.
She previously worked on Wall Street as an investor relations consultant for biotech and
DR. ANDREW J. ROCHMAN
Dr. Andrew J. Rochman is a NY Board-Certified Surgeon and a leader in advanced surgical techniques. He is a graduate of Colgate University and received his formal medical training from Nordestana University in 1981. He is an active member of the American Medical Association, the Medical Society of the State of New York, Nassau County Medical Society and the American College of Phlebology. Dr. Rochman currently manages several practices in the specialized sciences of advanced vein therapy, gallbladder surgery
In 2005, Dr. Rochman opened his private practice called ADVANCED VEIN CARE SOLUTIONS in Plainview, NY – for the treatment of vascular issues and disorders where he is recognized for his expertise in treating the full range of vein disease conditions using today’s most advanced diagnostic and treatment approaches.
In 2015, Dr. Rochman pursued training and received certification from U.S. Stem Cell for a comprehensive cellular regeneration program which led to the establishment of his second private practice – CELLULAR THERAPIES OF NY (CTNY). Here, he brings the advancements of stem cell therapy treatments to patients with musculoskeletal issues such as arthritis, knee/elbow & shoulder injuries. By the fall of 2017, CTNY underwent a major upgrade of its treatment capabilities and resources to promote the treatment of a wider variety of disorders
Kristin Comella, PhD
Dr. Comella is a world-renowned expert on regenerative medicine with a focus on
Dr. Comella has pioneered stem cell therapies from various sources including cord blood, bone marrow, muscle, and adipose. She led the team that gained the
She is currently serving as the Chief Scientific Officer and board member of US Stem Cell, a publicly traded company focusing on the discovery, development, and commercialization of autologous cell therapies for the treatment of degenerative diseases. She has been responsible for the development and implementation of cell therapies in the clinic for a variety of different indications for more than 7000 patients. Hundreds of practitioners
MICHELLE M. FORD